Article Text

Download PDFPDF

1182 Bispecific GPRC5D antibodies with potent cell-killing activity against multiple myeloma
  1. Hayley Roth,
  2. Ileine Sanchez,
  3. Breanna Tyrell,
  4. Anna Lobley,
  5. Trevor Barnes,
  6. Alyssa Cunningham,
  7. Nnenna Nwogu,
  8. Kyle Doolan,
  9. Benjamin Doranz,
  10. Joseph Rucker and
  11. Ross Chambers
  1. Integral Molecular, Philadelphia, PA, USA
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background GPRC5D is a G protein-coupled receptor that is expressed on multiple myeloma cells but absent from most healthy tissues except for hair follicles. Tumor-associated antigens like GPRC5D with little or no expression in healthy tissue are attractive targets for potent anti-tumor modalities including T cell-engaging bispecific antibodies. There is immense interest in GPRC5D as a multiple myeloma target, but currently no clinically approved therapies against it.

Methods Multipass membrane proteins are valuable therapeutic targets in oncology and other disease areas but are largely inaccessible as antibody targets due to their poor expression, membrane-dependent structure, small extracellular regions, and poor immunogenicity due to sequence conservation. We developed an antibody discovery platform (MPS) that specifically addresses each of these challenges. This platform utilizes advanced immunization techniques including DNA, mRNA, and Lipoparticles (virus-like particles). It also employs chickens as an evolutionarily divergent host species for robust immune responses against conserved targets. Antibodies raised in chickens are directly humanized prior to isolation reducing the need for downstream engineering. From the parental antibodies isolated, we engineered panels of GPRC5DxCD3 bispecific antibodies using multiple formats and CD3 arms, that encompass different geometries and binding stoichiometries, as these factors are expected to play a critical role for in vitro and in vivo potency.

Results We immunized chickens with GPRC5D and obtained high-titer immune responses. A subset of antibodies from this discovery program was configured as bispecific molecules using a CD3-targeting arm to bring tumor cells into close proximity with cytotoxic T cells that mediate cell killing. The molecules comprised multiple bispecific formats bearing different stoichiometries, geometries, and sizes, to enable identification of lead molecules with favorable activities and safety profiles. GPRC5D bispecifics displayed potent T cell-mediated cytotoxicity with picomolar potency. They also exhibited high specificity and bound to only their target, and not the other 6,000 proteins tested using a Membrane Proteome Array (MPA). Furthermore, these molecules showed good developability profiles and minimal cytokine release. GPRC5DxCD3 bispecifics are currently undergoing additional testing for developability and in vivo potency.

Conclusions GPRC5DxCD3 bispecific antibodies hold promise as potent and safe therapeutics for multiple myeloma

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.